BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:A. Menarini readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies A. Menarini's drugs run\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05596409-9037@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Elacestrant: Phase 2 readout est. (NCT05596409)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Rec
 eptor Positive\, HER-2 Negative Metastatic Breast Cancer Study\nEstimated 
 primary completion: November 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/elacestrant#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05596409
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06496243-401@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Obicetrapib: Phase 2 readout est. (NCT06496243)
DESCRIPTION:Obicetrapib\, phase 2\, Atherosclerotic Cardiovascular Disease.
 \nStudy: Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Level
 s\nEstimated primary completion: November 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/obicetrapib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06496243
URL:https://assetmemo.bio/drug/obicetrapib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05202509-401@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Obicetrapib: Phase 3 readout est. (NCT05202509)
DESCRIPTION:Obicetrapib\, phase 3\, Atherosclerotic Cardiovascular Disease.
 \nStudy: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapi
 b in Patients With Cardiovascular Disease\nEstimated primary completion: N
 ovember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obicetr
 apib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05202509
URL:https://assetmemo.bio/drug/obicetrapib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04442022-2266@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Selinexor: Phase 2/3 readout est. (NCT04442022)
DESCRIPTION:Selinexor\, phase 2/3.\nStudy: A Study of Rituximab-Gemcitabine
 -Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With
  Relapsed/Refractory Diffuse Large B-cell Lymphoma\nEstimated primary comp
 letion: December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/selinexor#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04442022
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05563220-9037@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:Elacestrant: Phase 1/2 readout est. (NCT05563220)
DESCRIPTION:Elacestrant\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elaces
 trant In Various Combination In Participants With Metastatic Breast Cancer
 \nEstimated primary completion: 27 December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/elacestrant#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05563220
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-2266@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Selinexor: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Selinexor\, phase 1/2\, Multiple Myeloma.\nStudy: Selinexor and
  Backbone Treatments of Multiple Myeloma Patients\nEstimated primary compl
 etion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/se
 linexor#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT02343042
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05980806-2266@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Selinexor: Phase 2 readout est. (NCT05980806)
DESCRIPTION:Selinexor\, phase 2\, Myelofibrosis.\nStudy: A Study of Selinex
 or Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Mod
 erate Thrombocytopenia\nEstimated primary completion: June 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/selinexor#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05980806
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07150975-190@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bofanglutide: Phase 3 readout est. (NCT07150975)
DESCRIPTION:Bofanglutide\, phase 3\, Obesity.\nStudy: Phase III Clinical St
 udy Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (
 Wegovy®) in Adult Obese or Overweight Subjects\nEstimated primary complet
 ion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bo
 fanglutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07150975
URL:https://assetmemo.bio/drug/bofanglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05386108-9037@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Elacestrant: Phase 1/2 readout est. (NCT05386108)
DESCRIPTION:Elacestrant\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Study of Abemaciclib and Elacestrant in Participants With Brain Met
 astasis Due to ER+/HER-2- Breast Cancer\nEstimated primary completion: Aug
 ust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/elacestrant
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT053
 86108
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493057-190@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20271114
DTEND;VALUE=DATE:20271115
SUMMARY:Bofanglutide: Phase 3 readout est. (NCT07493057)
DESCRIPTION:Bofanglutide\, phase 3\, Obesity.\nStudy: Evaluate the Efficacy
  and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Ap
 nea Not Treated With Positive Airway Pressure (PAP) Therapy\nEstimated pri
 mary completion: 14 November 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/bofanglutide#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07493057
URL:https://assetmemo.bio/drug/bofanglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04414475-2266@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Selinexor: Phase 2 readout est. (NCT04414475)
DESCRIPTION:Selinexor\, phase 2\, Multiple Myeloma.\nStudy: A Study of Seli
 nexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple M
 yeloma (MM)\, Seli and Bortezomib + LDD in Triple-class Refractory MM.\nEs
 timated primary completion: January 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/selinexor#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04414475
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219602-401@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Obicetrapib: Phase 3 readout est. (NCT07219602)
DESCRIPTION:Obicetrapib\, phase 3\, Type 2 Diabetes.\nStudy: A Study to Eva
 luate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or 
 Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering The
 rapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome\nEstim
 ated primary completion: March 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/obicetrapib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07219602
URL:https://assetmemo.bio/drug/obicetrapib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07794670-401@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Obicetrapib: Phase 2 readout est. (NCT07794670)
DESCRIPTION:Obicetrapib\, phase 2.\nStudy: Randomized Study to Evaluate the
  Effect of Obicetrapib in Participants With Preclinical Alzheimer's Diseas
 e\nEstimated primary completion: September 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/obicetrapib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07794670
URL:https://assetmemo.bio/drug/obicetrapib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07501832-190@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20280928
DTEND;VALUE=DATE:20280929
SUMMARY:Bofanglutide: Phase 3 readout est. (NCT07501832)
DESCRIPTION:Bofanglutide\, phase 3\, Obesity.\nStudy: Evaluate the Efficacy
  and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Ap
 nea Receiving Positive Airway Pressure (PAP) Therapy\nEstimated primary co
 mpletion: 28 September 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/bofanglutide#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07501832
URL:https://assetmemo.bio/drug/bofanglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07766018-9037@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Elacestrant: Phase 2 readout est. (NCT07766018)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Me
 tastatic Breast Cancer\nEstimated primary completion: October 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/elacestrant#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07766018
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492616-9037@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Elacestrant: Phase 3 readout est. (NCT06492616)
DESCRIPTION:Elacestrant\, phase 3\, Breast Cancer.\nStudy: A Study of Elace
 strant Versus Standard Endocrine Therapy in Women and Men With ER+\,HER2-\
 , Early Breast Cancer With High Risk of Recurrence\nEstimated primary comp
 letion: August 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 elacestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06492616
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
